Review: Testosterone and the metabolic syndrome

Therapeutic Advances in Endocrinology and Metabolism

Volumn 1, Issue 5, 2010, Pages 207-223

  Muraleedharan, Vakkat ^a   Jones, T Hugh ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b BARNSLEY DISTRICT GENERAL HOSPITAL   (United Kingdom)

Author keywords

diabetes; insulin resistance; metabolic syndrome; obesity; testosterone deficiency

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; GONADORELIN AGONIST; PLACEBO; TESTOSTERONE; TESTOSTERONE ESTER; TESTOSTERONE UNDECANOATE;

ANDROGEN DEFICIENCY; ANDROGEN DEPRIVATION THERAPY; ANDROGEN THERAPY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DIET THERAPY; DRUG MECHANISM; DYSLIPIDEMIA; EDEMA; EVENING DOSAGE; EXERCISE; HORMONE ACTION; HUMAN; HYPERTENSION; HYPOGONADISM; INSULIN RESISTANCE; METABOLIC SYNDROME X; MORNING DOSAGE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OBSERVATIONAL STUDY; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SYNCOPE;

EID: 79952848518     PISSN: 20420188     EISSN: None     Source Type: Journal    
DOI: 10.1177/2042018810390258     Document Type: Review

References (145)

1. Agarwal, P.K. and Oefelein, M.G. ( 2005) Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 173: 533-536.
2. Agledahl, I., Hansen, J.B. and Svartberg, J. ( 2008) Impact of testosterone treatment on postprandial triglyceride metabolism in elderly men with subnormal testosterone levels. Scand J Clin Lab Investig 68: 641-648.
3. Alberti, K.G.M.M., Eckel, R.H., Grundy, S.M., Zimmet, P.Z., Cleeman, J.I., Donato, K.A. et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120: 1640-1645.
4. Alexandersen, P., Haarbo, J., Byrjalsen, I., Lawaetz, H. and Christiansen, C. ( 1999) Natural androgens inhibit male atherosclerosis-a study in castrated, cholesterol-fed rabbits. Circulat Res 84: 813-819.
5. Anderson, F.H., Francis, R.M. and Faulkner, K. ( 1996) Androgen supplementation in eugonadal men with osteoporosis-effects of 6 months of treatment on bone mineral density and cardiovascular risk factors. Bone 18: 171-177.
6. Araujo, A.B., Kupelian, V., Page, S.T., Handelsman, D.J., Bremner, W.J. and McKinlay, J.B. ( 2007) Sex steroids and all-cause and cause-specific mortality in men. Arch Intern Med 167: 1252-1260.
7. Bagatell, C.J., Heiman, J.R., Matsumoto, A.M., Rivier, J.E. and Bremner, W.J. ( 1994) Metabolic and
8. behavioral-effects of high-dose, exogenous testosterone in healthy-men. J Clin Endocrinol Metab 79: 561-567.
9. Barrettconnor, E. ( 1992) Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes-mellitus. Ann Intern Med 117: 807-811.
10. Basaria, S., Coviello, A.D., Travison, T.G., Storer, T.W., Farwell, W.R., Jette, A.M. et al (2010) Adverse events associated with testosterone administration. N Engl J Med 363: 109-122.
11. Bhasin, S., Cunningham, G.R., Hayes, F.J., Matsumoto, A.M., Snyder, P.J., Swerdloff, R.S. et al (2010) Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 95: 2536-2559.
12. Blouin, K., Despres, J.P., Couillard, C., Tremblay, A., Prud'homme, D., Bouchard, C. et al (2005) Contribution of age and declining androgen levels to features of the metabolic syndrome in men. Metab Clin Exp 54: 1034-1040.
13. Bocchi, E.A., Carvalho, V.O. and Guimaraes, G.V. ( 2008) Inverse correlation between testosterone and ventricle ejection fraction, hemodynamics and exercise capacity in heart failure patients with erectile dysfunction. Int Braz J Urol 34: 302-310; discussion 310-302.
14. Bojesen, A., Juul, S., Birkebaek, N.H. and Gravholt, C.H. ( 2006) Morbidity in Klinefelter syndrome: a Danish register study based on hospital discharge diagnoses. J Clin Endocrinol Metab 91: 1254-1260.
15. Boyanov, M.A., Boneva, Z. and Christov, V.G. ( 2003) Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 6: 1-7.
16. Calof, O.M., Singh, A.B., Lee, M.L., Kenny, A.M., Urban, R.J., Tenover, J.L. et al (2005) Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol Ser A-Biol Sci Med Sci 60 (11): 1451-1457.
17. Chubb, S.A.P., Hyde, Z., Almeida, O.P., Flicker, L., Norman, P.E., Jamrozik, K. et al (2008) Lower sex hormone-binding globulin is more strongly associated with metabolic syndrome than lower total testosterone in older men: the Health in Men Study. Eur J Endocrinol 158: 785-792.
18. Cohen, P.G. ( 1999) The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt-a major factor in the genesis of morbid obesity. Med Hypoth 52: 49-51.
19. Cohen, P.G. ( 2001) Aromatase, adiposity, aging and disease. The hypogonadal metabolic-atherogenicdisease and aging connection. Med Hypoth 56: 702-708.
20. Cohen, P.G. ( 2008) The hypoandrogenic-anabolic deficiency state: Endocrine and metabolic shifts in men. Med Hypoth 71: 805-807.
21. Corona, G., Mannucci, E., Forti, G. and Maggi, M. ( 2009) Hypogonadism, E.D., metabolic syndrome and obesity: A pathological link supporting cardiovascular diseases. Int J Androl 32: 587-598.
22. Corona, G., Mannucci, E., Schulman, C., Petrone, L., Mansani, R., Cilotti, A. et al (2006) Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunction. Eur Urol 50: 595-604.
23. Corrales, J.J., Almeida, M., Burgo, R., Mories, M.T., Miralles, J.M. and Orfao, A. ( 2006) Androgen-replacement therapy depresses the ex vivo production of inflammatory cytokines by circulating antigen-presenting cells in aging type-2 diabetic men with partial androgen deficiency. J Endocrinol 189: 595-604.
24. D'Agostino, P., Milano, S., Barbera, C., Di Bella, G., LaRosa, M., Ferlazzo, V. et al (1999) Sex hormones modulate inflammatory mediators produced by macrophages, In: Cutolo, M., Masi, A.T., Bijlsma, J.W.J., Chikanza, I.C., Bradlow, H.L. and Castagnetta, L. (eds). Neuroendocrine Immune Basis of the Rheumatic Diseases, Vol. 876, New York Academy of Sciences: New York, pp. 426-429.
25. de Pergola, G. ( 2000) The adipose tissue metabolism: role of testosterone and dehydroepiandrosterone. Int J Obesity 24: S59-S63.
26. Demirbag, R., Yilmaz, R., Ulucay, A. and Unlu, D. ( 2005) The inverse relationship between thoracic aortic intima media thickness and testosterone level. Endocrine Res 31: 335-344.
27. Derweesh, I.H., DiBlasio, C.J., Kincade, M.C., Malcolm, J.B., Lamar, K.D., Patterson, A.L. et al (2007) Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU Int 100: 1060-1065.
28. Dhindsa, S., Prabhakar, S., Sethi, M., Bandyopadhyay, A., Chaudhuri, A. and Dandona, P. ( 2004) Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 89: 5462-5468.
29. Diaz-Arjonilla, M., Schwarcz, M., Swerdloff, R.S. and Wang, C. ( 2009) Obesity, low testosterone levels and erectile dysfunction. Int J Impotence Res 21: 89-98.
30. Ding, E.L., Song, Y., Malik, V.S. and Liu, S. ( 2006) Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 295: 1288-1299.
31. Fan, A.Z. and Dwyer, J.H. ( 2007) Sex differences in the relation of HDL cholesterol to progression of carotid intima-media thickness: the Los Angeles Atherosclerosis Study. Atherosclerosis 195: e191-e196.
32. Fernandez-Balsells, M.M., Murad, M.H., Lane, M., Lampropulos, J.F., Albuquerque, F., Mullan, R.J. et al (2010) Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrin Metab 95 (6): 2560-2575.
33. Fukui, M., Kitagawa, Y., Nakamura, N., Kadono, M., Mogami, S., Hirata, C. et al (2003) Association between serum testosterone concentration and carotid atherosclerosis in men with type 2 diabetes. Diabetes Care 26: 1869-1873.
34. Gapstur, S.M., Gann, P.H., Kopp, P., Colangelo, L., Longcope, C. and Liu, K. ( 2002) Serum androgen concentrations in young men: A longitudinal analysis of associations with age, obesity, and race. The CARDIA Male Hormone Study. Cancer Epidemiol Biomarkers Prevention 11: 1041-1047.
35. Garaulet, M., Perez-Llamas, F., Fuente, T., Zamora, S. and Tebar, F.J. ( 2000) Anthropometric, computed tomography and fat cell data in an obese population: relationship with insulin, leptin, tumor factor-alpha, sex hormone-binding globulin and sex hormones. Eur J Endocrinol 143: 657-666.
36. Gornstein, R.A., Lapp, C.A., Bustos-Valdes, S.M. and Zamorano, P. ( 1999) Androgens modulate interleukin-6 production by gingival fibroblasts in vitro. J Periodontol 70: 604-609.
37. Grossmann, M., Gianatti, E.J. and Zajac, J.D. ( 2010) Testosterone and type 2 diabetes. Curr Opin Endocrinol Diabetes Obesity 17: 247-256.
38. Haddad, R.M., Kennedy, C.C., Caples, S.M., Tracz, M.J., Bolona, E.R., Sideras, K. et al (2007) Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 82 (1): 29-39.
39. Haffner, S.M., Karhapaa, P., Mykkanen, L. and Laakso, M. ( 1994) Insulin-resistance, body-fat distribution, and sex-hormones in men. Diabetes 43: 212-219.
40. Haffner, S.M., Shaten, J., Stern, M.P., Smith, G.D. and Kuller, L. ( 1996) Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. Am J Epidemiol 143: 889-897.
41. Haffner, S.M., Valdez, R.A., Stern, M.P. and Katz, M.S. ( 1993) Obesity, body-fat distribution and sex-hormones in men. Int J Obesity 17: 643-649.
42. Hak, A.E., Witteman, J.C.M., de Jong, F.H., Geerlings, M.I., Hofman, A. and Pols, H.A.P. ( 2002) Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: The Rotterdam study. J Clin Endocrinol Metab 87: 3632-3639.
43. Hanefeld, M., Koehler, C., Gallo, S., Benke, I. and Ott, P. ( 2007) Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study. Cardiovasc Diabetol 6: 13.
44. Haring, R., Volzke, H., Steveling, A., Krebs, A., Felix, S.B., Schofl, C. et al (2010) Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. Eur Heart J 31 (12): 1494-1501.
45. Hatakeyama, H., Nishizawa, M., Nakagawa, A., Nakano, S., Kigoshi, T. and Uchida, K. ( 2002) Testosterone inhibits tumor necrosis factor-alpha-induced vascular cell adhesion molecule-1 expression in human aortic endothelial cells. FEBS Lett 530: 129-132.
46. Hayes, F.J., Decruz, S., Seminara, S.B., Boepple, P.A. and Crowley, W.F. ( 2001) Differential regulation of gonadotropin secretion by testosterone in the human male: Absence of a negative feedback effect of testosterone on follicle-stimulating hormone secretion. J Clin Endocrinol Metab 86: 53-58.
47. Hayes, F.J., Seminara, S.B., Decruz, S., Boepple, P.A. and Crowley, W.F. ( 2000) Aromatase inhibition in the human male reveals a hypothalamic site of estrogen feedback. J Clin Endocrinol Metab 85: 3027-3035.
48. Heufelder, A.E., Saad, F., Bunck, M.C. and Gooren, L. (2009) Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 30: 726-733.
49. Hill, S., Arutchelvam, V. and Quinton, R. (2009) Enclomiphene, an estrogen receptor antagonist for the treatment of testosterone deficiency in men. IDrugs 12: 109-119.
50. Hofbauer, L.C., Ten, R.M. and Khosla, S. ( 1999) The anti-androgen hydroxyflutamide and androgens inhibit interleukin-6 production by an androgen-responsive human osteoblastic cell line. J Bone Mineral Res 14: 1330-1337.
51. Johannsson, G., Gibney, J., Wolthers, T., Leung, K.C. and Ho, K.K.Y. ( 2005) Independent and combined effects of testosterone and growth hormone on extracellular water in hypopituitary men. J Clin Endocrinol Metab 90: 3989-3994.
52. Johnsen, S.H., Mathiesen, E.B., Fosse, E., Joakimsen, O., Stensland-Bugge, E., Njolstad, I. et al (2005) Elevated high-density lipoprotein cholesterol levels are protective against plaque progression-a follow-up study of 1952 persons with carotid atherosclerosis-The Tromso study. Circulation 112: 498-504.
53. Jones, H., Howell, J. and Channer, K. ( 2010) Testosterone improves glycaemic control, insulin resistance, body fat and sexual function in men with the metabolic syndrome and/or type 2 diabetes: a Multicentre European Clinical Trial: the TIMES 2 Study. Endocrine Abstracts 21: OC1.6.
54. Jones, T.H. ( 2007) Testosterone associations with erectile dysfunction, diabetes, and the metabolic syndrome. Eur Urol Suppl 6: 847-857.
55. Jones, T.H. (2010) Testosterone deficiency: a risk factor for cardiovascular disease ? Trends Endocrinol Metab 21: 496-503.
56. Jones, T.H. and Saad, F. (2009) The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis 207: 318-327.
57. Kapoor, D., Aldred, H., Clark, S., Channer, K.S. and Jones, T.H. ( 2007a) Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 30: 911-917.
58. Kapoor, D., Clarke, S., Channer, K.S. and Jones, T.H. ( 2007b) Erectile dysfunction is associated with low bioactive testosterone levels and visceral adiposity in men with type 2 diabetes. Int J Androl 30: 500-507.
59. Kapoor, D., Clarke, S., Stanworth, R., Channer, K.S. and Jones, T.H. ( 2007c) The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol 156: 595-602.
60. Kapoor, D., Goodwin, E., Channer, K.S. and Jones, T.H. ( 2006) Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 154: 899-906.
61. Kapoor, D., Malkin, C.J., Channer, K.S. and Jones, T.H. ( 2005) Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf) 63: 239-250.
62. Keating, N.L., O'Malley, A.J. and Smith, M.R. ( 2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24: 4448-4456.
63. Kenny, A.M., Gruman, C.A., Fabregas, G., Biskup, B. and Mansoor, G. ( 2001) Effects of testosterone on lipids and vascular reactivity in older men. Gerontologist 41: 185-185.
64. Khaw, K.-T., Dowsett, M., Folkerd, E., Bingham, S., Wareham, N., Luben, R. et al (2007) Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European Prospective Investigation Into Cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 116: 2694-2701.
65. Khaw, K.T. and Barrett-Connor, E. ( 1992) Lower endogenous androgens predict central adiposity in men. Ann Epidemiol 2: 675-682.
66. Khaw, K.T. and Barrettconnor, E. ( 1988) Blood-pressure and endogenous testosterone in men-an inverse relationship. J Hypertension 6: 329-332.
67. Kupelian, V., Page, S.T., Araujo, A.B., Travison, T.G., Bremner, W.J. and McKinlay, J.B. ( 2006) Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 91: 843-850.
68. Kylin, E. ( 1923) Studien über das Hypertonie-Hyperglykämie-Hyperurikämiesyndrom. Zentrabl f innere Med Leipz 181: 105-127.
69. Laaksonen, D.E., Niskanen, L., Punnonen, K., Nyyssonen, K., Tuomainen, T.P., Salonen, R. et al (2003) Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur J Endocrinol 149: 601-608.
70. Laaksonen, D.E., Niskanen, L., Punnonen, K., Nyyssonen, K., Tuomainen, T.P., Valkonen, V.P. et al (2005) The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab 90: 712-719.
71. Laaksonen, D.E., Niskanen, L., Punnonen, K., Nyyssonen, K., Tuomainen, T.P., Valkonen, V.P. et al (2004) Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 27: 1036-1041.
72. Lanfranco, F., Zitzmann, M., Simoni, M. and Nieschlag, E. ( 2004) Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy. Clin Endocrinol 60: 500-507.
73. Laughlin, G.A., Barrett-Connor, E. and Bergstrom, J. ( 2008) Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 93: 68-75.
74. Li, Z.G., Danis, V.A. and Brooks, P.M. ( 1993) Effect of gonadal-steroids on the production of IL-1 and IL-6 by blood mononuclear-cells invitro. Clin Exp Rheumatol 11: 157-162.
75. Liva, S.M. and Voskuhl, R.R. ( 2001) Testosterone acts directly on CD4(+) T lymphocytes to increase IL-10 production. J Immunol 167: 2060-2067.
76. Makhsida, N., Shah, J., Yan, G., Fisch, H. and Shabsigh, R. ( 2005) Hypogonadism and metabolic syndrome: Implications for testosterone therapy. J Urol 174: 827-834.
77. Malkin, C.J., Pugh, P.J., Morris, P.D., Asif, S., Jones, T.H. and Channer, K.S. ( 2010) Low serum testosterone and increased mortality in men with coronary heart disease. Heart, http://heart.bmj.com/content/early/2010/09/28/hrt.2010.195412.abstract. Published Online First 19 October 2010.
78. Malkin, C.J., Pugh, P.J., Jones, R.D., Kapoor, D., Channer, K.S. and Jones, T.H. ( 2004a) The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 89: 3313-3318.
79. Malkin, C.J., Pugh, P.J., Morris, P.D., Kerry, K.E., Jones, R.D., Jones, T.H. et al (2004 b) Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 90: 871-876.
80. Maravelias, C., Dona, A., Stefanidou, M. and Spiliopoulou, C. ( 2005) Adverse effects of anabolic steroids in athletes-a constant threat. Toxicol Lett 158: 167-175.
81. Marin, P., Holmang, S., Gustafsson, C., Jonsson, L., Kvist, H., Elander, A. et al (1993) Androgen treatment of abdominally obese men. Obes Res 1: 245-251.
82. Marin, P., Oden, B. and Bjorntorp, P. ( 1995) Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose-tissue in-vivo in men-effects of androgens. J Clin Endocrinol Metab 80: 239-243.
83. Maron, D.J. ( 2000) The epidemiology of low levels of high-density lipoproteins cholesterol in patients with and without coronary artery disease. Am J Cardiol 86(12A): 11L-14L.
84. Messerli, F.H., Garavaglia, G.E., Schmieder, R.E., Sundgaardriise, K., Nunez, B.D. and Amodeo, C. ( 1987) Disparate cardiovascular findings in men and women with essential-hypertension. Ann Intern Med 107: 158-161.
85. Mottram, D.R. and George, A.J. ( 2000) Anabolic steroids. Best Pract Res Clin Endocrinol Metab 14: 55-69.
86. Muller, M., van den Beld, A.W., Bots, M.L., Grobbee, D.E., Lamberts, S.W. and van der Schouw, Y.T. ( 2004) Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation 109: 2074-2079.
87. Muraleedharan, V., Ranjan, N., Rolfe, C. and Jones, T.H. ( 2010) The effect of testosterone undecanoate on cardiovascular risk factors in men with hypogonadism in clinical practice. Endocrine Abstracts 31(3 Suppl.1): S464.
88. Nettleship, J.E., Jones, T.H., Channer, K.S. and Jones, R.D. ( 2007a) Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: An effect that is independent of the classic androgen receptor. Circulation 116: 2427-2434.
89. Nettleship, J.E., Pugh, P.J., Channer, K.S., Jones, T. and Jones, R.D. ( 2007b) Inverse Relationship between Serum Levels of Interleukin-1? and Testosterone in Men with Stable Coronary Artery Disease. Hormone Metab Res 39: 366-371.
90. Oh, J.Y., Barrett-Connor, E., Wedick, N.M. and Wingard, D.L. ( 2002) Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo Study. Diabetes Care 25: 55-60.
91. Olufadi, R. and Byrne, C.D. ( 2008) Clinical and laboratory diagnosis of the metabolic syndrome. J Clin Pathol 61: 697-706.
92. Pasquali, R., Casimirri, F., Balestra, V., Flamia, R., Melchionda, N., Fabbri, R. et al (1991) The relative contribution of androgens and insulin in determining abdominal body-fat distribution in premenopausal women. J Endocrinol Invest 14: 839-846.
93. Pitteloud, N., Mootha, V.K., Dwyer, A.A., Hardin, M., Lee, H., Eriksson, K.F. et al (2005) Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 28: 1636-1642.
94. Reaven, G.M. ( 1988) Role of insulin resistance in human-disease. Diabetes 37: 1595-1607.
95. Rebuffescrive, M., Marin, P. and Bjorntorp, P. ( 1991) Effect of testosterone on abdominal adipose-tissue in men. Int J Obesity 15: 791-795.
96. Reckelhoff, J.F., Yanes, L.L., Iliescu, R., Fortepiani, L.A. and Granger, J.P. ( 2005) Testosterone supplementation in aging men and women: possible impact on cardiovascular-renal disease. Am J Physiol Renal Physiol 289: F941-F948.
97. Reckelhoff, J.F., Zhang, H.M. and Granger, J.P. ( 1998) Androgen receptor antagonism attenuates the progression of hypertension in male spontaneously hypertensive rats. Hypertension 32: 69.
98. Rodriguez, A., Muller, D.C., Metter, E.J., Maggio, M., Harman, S.M., Blackman, M.R. et al (2007) Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab 92: 3568-3572.
99. Saad, F., Gooren, L., Haider, A. and Yassin, A. ( 2007) An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome. Arch Androl 53: 353-357.
100. Saad, F., Gooren, L.J., Haider, A. and Yassin, A. ( 2008) A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J Androl 29: 102-105.
101. Seidell, J.C., Bjorntorp, P., Sjostrom, L., Kvist, H. and Sannerstedt, R. ( 1990) Visceral fat accumulation in men is positively associated with insulin, glucose, and c-peptide levels, but negatively with testosterone levels. Metab Clin Exp 39: 897-901.
102. Selvin, E., Nelson, W.G., Feinleib, M., Dobs, A., Zhang, L., Basaria, S. et al (2007) Androgens and diabetes in men-Results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 30: 234-238.
103. Shabsigh, R., Arver, S., Channer, K.S., Eardley, I., Fabbri, A., Gooren, L. et al (2008) The triad of erectile dysfunction, hypogonadism and the metabolic syndrome. Int J Clin Pract 62: 791-798.
104. Shores, M.M., Matsumoto, A.M., Sloan, K.L. and Kivlahan, D.R. ( 2006) Low serum testosterone and mortality in male veterans. Arch Intern Med 166: 1660-1665.
105. Simon, D., Charles, M.A., Nahoul, K., Orssaud, G., Kremski, J., Hully, V. et al (1997) Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. J Clin Endocrinol Metab 82: 682-685.
106. Simon, D., Preziosi, P., Barrettconnor, E., Roger, M., Saintpaul, M., Nahoul, K. et al (1992) Interrelation between plasma testosterone and plasma-insulin in healthy adult men-the Telecom study. Diabetologia 35: 173-177.
107. Simons, L.A., McCallum, J., Friedlander, Y. and Simons, J. ( 1998) Risk factors for ischemic stroke-Dubbo Study of the elderly. Stroke 29: 1341-1346.
108. Singh, R., Artaza, J.N., Taylor, W.E., Gonzalez-Cadavid, N.F. and Bhasin, S. ( 2003) Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology 144: 5081-5088.
109. Smith, A.M., English, K.M., Malkin, C.J., Jones, R.D., Jones, T.H. and Channer, K.S. ( 2005a) Testosterone does not adversely affect fibrinogen or tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) levels in 46 men with chronic stable angina. Eur J Endocrinol 152: 285-291.
110. Smith, G.D., Ben-Shlomo, Y., Beswick, A., Yarnell, J., Lightman, S. and Elwood, P. ( 2005b) Cortisol, testosterone, and coronary heart disease: prospective evidence from the Caerphilly Study. Circulation 112: 332-340.
111. Smith, J.C., Bennett, S., Evans, L.M., Kynaston, H.G., Parmar, M., Mason, M.D. et al (2001) The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86: 4261-4267.
112. Stanworth, R., Kapoor, D., Channer, K. and Jones, T. ( 2008) Androgen receptor CAG repeat polymorphism is associated with serum testosterone levels, obesity and serum leptin in men with type 2 diabetes. Eur J Endocrinol EJE-08-0266.
113. Stanworth, R.D. and Jones, T.H. (2009) Testosterone in obesity, metabolic syndrome and type 2 diabetes. Adv Managem Testosterone Deficiency 37: 74-90.
114. Stanworth, R.D., Kapoor, D., Channer, K.S. and Jones, T.H. ( 2007) Testosterone levels correlate positively with HDL cholesterol levels in men with type 2 diabetes. Endocrine Abstracts 14: P628.
115. Stellato, R.K., Feldman, H.A., Hamdy, O., Horton, E.S. and McKinlay, J.B. ( 2000) Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men-Prospective results from the Massachusetts Male Aging Study. Diabetes Care 23: 490-494.
116. Sullivan, M.L., Martinez, C.M., Gennis, P. and Gallagher, E.J. ( 1998) The cardiac toxicity of anabolic steroids. Prog Cardiovasc Dis 41: 1-15.
117. Svartberg, J., Von Muhlen, D., Mathiesen, E., Joakimsen, O., Bonaa, K.H. and Stensland-Bugge, E. ( 2006) Low testosterone levels are associated with carotid atherosclerosis in men. J Intern Med 259: 576-582.
118. Svartberg, J., von Muhlen, D., Schirmer, H., BarrettConnor, E., Sundfjord, J. and Jorde, R. (2004) Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromso Study. Eur J Endocrinol 150: 65-71.
119. Tivesten, A., Vandenput, L., Labrie, F., Karlsson, M.K., Ljunggren, A., Mellström, D. et al (2009) Low serum testosterone and estradiol predict mortality in elderly men. J Clin Endocr Metab 94 (7): 2482-2488.
120. Thompson, P.D., Cullinane, E.M., Sady, S.P., Chenevert, C., Saritelli, A.L., Sady, M.A. et al (1989) Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 261: 1165-1168.
121. Tomaszewski, M., Charchar, F.J., Maric, C., Kuzniewicz, R., Gola, M., Grzeszczak, W. et al (2009) Association between lipid profile and circulating concentrations of estrogens in young men. Atherosclerosis 203: 257-262.
122. Traish, A.M., Guay, A., Feeley, R. and Saad, F. (2009) The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J Androl 30: 10-22.
123. Tsai, E.C., Boyko, E.J., Leonetti, D.L. and Fujimoto, W.Y. ( 2000) Low serum testosterone level as a predictor of increased visceral fat in Japanese-American men. Int J Obesity 24: 485-491.
124. Tsai, E.C., Fujimoto, W.Y., Matsumoto, A.M. and Boyko, E.J. ( 2004) Association of bioavailable, free, and total testosterone with insulin resistance-influence of sex hormone-binding globulin and body fat. Diabetes Care 27: 861-868.
125. Uyanik, B.S., Ari, Z., Gumus, B., Yigitoglu, R. and Arslan, T. ( 1997) Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men-a placebo controlled study. Japanese Heart J 38: 73-82.
126. Vikan, T., Schirmer, H., Njolstad, I. and Svartberg, J. (2009) Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men: the Tromso Study. Eur J Endocrinol 161 (3): 435-442.
127. Vague, J. ( 1947) Sexual differentiation. A factor affecting the forms of obesity. Presse Med 30: 339-340.
128. Vaidya, D., Dobs, A., Gapstur, S.M., Golden, S.H., Hankinson, A., Liu, K. et al (2008) The association of endogenous sex hormones with lipoprotein subtraction profile in the Multi-Ethnic Study of Atherosclerosis. Metab Clin Exp 57: 782-790.
129. van Pottelbergh, I., Braeckman, L., de Bacquer, D., de Backer, G. and Kaufman, J.M. ( 2003) Differential contribution of testosterone and estradiol in the determination of cholesterol and lipoprotein profile in healthy middle-aged men. Atherosclerosis 166: 95-102.
130. Vermeulen, A., Goemaere, S. and Kaufman, J.M. ( 1999) Testosterone, body composition and aging. J Endocrinol Invest 22(5 Suppl): 110-116.
131. Vermeulen, A., Kaufman, J.M., Goemaere, S. and van Pottelberg, I. ( 2002) Estradiol in elderly men. Aging Male 5: 98-102.
132. Wang, C., Nieschlag, E., Swerdloff, R., Behre, H.M., Hellstrom, W.J., Gooren, I.J. et al (2008) Investigation, treatment and monitoring of late-onset hypogonadism in males. Eur J Endocrinol 159: 507-514.
133. Whitsel, E.A., Boyko, E.J., Matsumoto, A.M., Anawalt, B.D. and Siscovick, D.S. ( 2001) Intramuscular testosterone esters and plasma lipids in hypogonadal men: A meta-analysis. Am J Med 111: 261-269.
134. WHO (2010) Global strategy on diet, physical activity and health - Obesity and Overweight. http://www.who.int/dietphysicalactivity/publications/facts/obesity/en/
135. Yanase, T., Fan, W., Kyoya, K., Min, L., Takayanagi, R., Kato, S. et al (2008) Androgens and metabolic syndrome: Lessons from androgen receptor knock out (ARKO) mice. J Steroid Biochem Mol Biol 109: 254-257.
136. Yassin, A.A., Saad, F. and Gooren, L.J. ( 2008) Metabolic syndrome, testosterone deficiency and erectile dysfunction never come alone. Andrologia 40: 259-264.
137. Yasui, T., Uemura, H., Irahara, M., Arai, M., Kojimahara, N., Okabe, R. et al (2008) Associations of endogenous sex hormones and sex hormone-binding globulin with lipid profiles in aged Japanese men and women. Clin Chim Acta 398: 43-47.
138. Yialamas, M.A., Dwyer, A.A., Hanley, E., Lee, H., Pitteloud, N. and Hayes, F.J. ( 2007) Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 92: 4254-4259.
139. Yusuf, S., Hawken, S., Ounpuu, S., Dans, T., Avezum, A., Lanas, F. et al (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364: 937-952.
140. Zgliczynski, S., Ossowski, M., SlowinskaSrzednicka, J., Brzezinska, A., Zgliczynski, W., Soszynski, P. et al (1996) Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis 121: 35-43.
141. Zitzmann, M. (2009) Testosterone deficiency, insulin resistance and the metabolic syndrome. Nature Rev Endocrinol 5: 673-681.
142. Zitzmann, M., Brune, M., Kornmann, B., Gromoll, J., von Eckardstein, S., von Eckardstein, A. et al (2001) The CAG repeat polymorphism in the AR gene affects high density lipoprotein cholesterol and arterial vasoreactivity. J Clin Endocrinol Metab 86: 4867-4873.
143. Zitzmann, M. and Nieschlag, E. ( 2003) The CAG repeat polymorphism within the androgen receptor gene and maleness. Int J Androl 26: 76-83.
144. Zitzmann, M. and Nieschlag, E. ( 2007) Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab 92: 3844-3853.
145. Zumoff, B., Strain, G.W., Miller, L.K., Rosner, W., Senie, R., Seres, D.S. et al (1990) Plasma-free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab 71: 929-931.